CL2019001668A1 - Composiciones cannabinoides novedosas y métodos para tratar la epilepsia infantil. - Google Patents

Composiciones cannabinoides novedosas y métodos para tratar la epilepsia infantil.

Info

Publication number
CL2019001668A1
CL2019001668A1 CL2019001668A CL2019001668A CL2019001668A1 CL 2019001668 A1 CL2019001668 A1 CL 2019001668A1 CL 2019001668 A CL2019001668 A CL 2019001668A CL 2019001668 A CL2019001668 A CL 2019001668A CL 2019001668 A1 CL2019001668 A1 CL 2019001668A1
Authority
CL
Chile
Prior art keywords
methods
childhood epilepsy
cannabinoid compositions
novel cannabinoid
treating childhood
Prior art date
Application number
CL2019001668A
Other languages
English (en)
Spanish (es)
Inventor
Catherine Jacobson
Caleb Joshua Eades
Original Assignee
Tilray Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tilray Inc filed Critical Tilray Inc
Publication of CL2019001668A1 publication Critical patent/CL2019001668A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
CL2019001668A 2016-12-20 2019-06-17 Composiciones cannabinoides novedosas y métodos para tratar la epilepsia infantil. CL2019001668A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662436861P 2016-12-20 2016-12-20

Publications (1)

Publication Number Publication Date
CL2019001668A1 true CL2019001668A1 (es) 2019-09-06

Family

ID=61028091

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001668A CL2019001668A1 (es) 2016-12-20 2019-06-17 Composiciones cannabinoides novedosas y métodos para tratar la epilepsia infantil.

Country Status (12)

Country Link
US (1) US20200215022A1 (enExample)
EP (1) EP3558297A1 (enExample)
JP (2) JP2020514282A (enExample)
KR (1) KR20190099221A (enExample)
AU (1) AU2017381587A1 (enExample)
BR (1) BR112019012776A2 (enExample)
CA (1) CA3046320A1 (enExample)
CL (1) CL2019001668A1 (enExample)
CO (1) CO2019006911A2 (enExample)
MX (1) MX2019007496A (enExample)
PE (1) PE20200338A1 (enExample)
WO (1) WO2018115962A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
IL261132A (en) * 2018-08-13 2018-11-04 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
GB2580653A (en) * 2019-01-21 2020-07-29 Gw Res Ltd Use of cannabinoids in the treatment of comorbidities associated with epilepsy
EP3931330A4 (en) 2019-02-25 2023-03-15 Ginkgo Bioworks, Inc. BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS
US11622956B1 (en) 2019-06-26 2023-04-11 RCR BioPharma Compound and method for treating diseases and disorders
GB202009321D0 (en) 2020-06-18 2020-08-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2598922A (en) 2020-09-18 2022-03-23 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
CA3217137A1 (en) 2021-04-29 2022-11-03 Christopher Adair Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
WO2023047308A1 (en) * 2021-09-22 2023-03-30 Avicanna Inc. Methods for reducing or eliminating incidence of seizures and sudden unexpected death in epilepsy
WO2023200906A1 (en) 2022-04-12 2023-10-19 Shackelford Pharma Inc. Treatment of seizure disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1361864T3 (en) * 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
GB2530001B (en) * 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531282A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
CA2970651C (en) * 2014-12-12 2020-09-29 Ojai Energetics Pbc Microencapsulated cannabinoid compositions
BR112017018944A2 (en) * 2015-03-02 2018-05-15 Afgin Pharma, Llc method of treating a disease state or condition in humans with a carbinoid drug, and method of treating a disease state or condition in a mammal other than a human with carbinoid drug (s)
WO2017137992A1 (en) * 2016-02-11 2017-08-17 Gelpell Ag Oral solid cannabinoid formulations, methods for producing and using thereof

Also Published As

Publication number Publication date
EP3558297A1 (en) 2019-10-30
CA3046320A1 (en) 2018-06-28
KR20190099221A (ko) 2019-08-26
BR112019012776A2 (pt) 2019-12-10
CO2019006911A2 (es) 2019-08-30
PE20200338A1 (es) 2020-02-14
US20200215022A1 (en) 2020-07-09
MX2019007496A (es) 2019-10-30
AU2017381587A1 (en) 2019-06-20
JP2023001138A (ja) 2023-01-04
JP2020514282A (ja) 2020-05-21
WO2018115962A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
CO2019006911A2 (es) Composiciones cannabinoides novedosas y métodos para tratar la epilepsia infantil.
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
MX2018007987A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
BR112019018124A2 (pt) composições e métodos para imunooncologia
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
MX377365B (es) Composiciones y métodos para tratar rosácea y acné.
BR112017024134A2 (pt) adaptação de taxa para agregação lte-wlan.
CR20170131A (es) Anticuerpos anti-her2 e inmunoconjugados
BR112016024043A2 (pt) sistemas e métodos para o compartilhamento de frota de veículos.
MX2016012880A (es) Cadena j modificada.
MX389663B (es) Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
CR20150482A (es) Anticuerpos e inmunoconjugados anti-b7-h4
CO2017005941A2 (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
CO7151529A2 (es) Anticuerpos anti-cd22 e inmunoconjugados
EP3445212A4 (en) GRINDERS, ANALYZERS AND RELATED TECHNOLOGIES
BR112018006696A2 (pt) métodos e sistemas para obter óleo a partir de uma composição de vinhoto
CO2018005393A2 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos
BR112016026544A2 (pt) métodos para inibir a necroptose
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
BR112017014598A2 (pt) métodos e usos para hidrólise de queratina
MX2017012553A (es) Compuestos espirociclicos.
FR3016933B1 (fr) Installation de pompage d'hydrocarbures, module et procede.
BR112017024699A2 (pt) Composição de sal organometálico, método para preparar uma composição de sal organometálico e composição lubrificante